According to the results of the DAPA trial, prophylactic implantation of an implantable cardioverter defibrillator within 90 days in patients with STEMI undergoing PCI reduced the risk for death in certain high-risk patients.

The results were presented by DM Haanschoten, MD, at the Heart Rhythm Society congres in San Francisco.

The DAPA trial is a prospective, randomized study of patients at high risk for sudden death who had PCI to treat STEMI and were assigned ICD implantation plus conventional medical therapy or conventional medical therapy alone.

In total 266 patients were enrolled. During a median follow-up of 9 years, 24.4% of patients in the ICD group died compared with 35.6% of patients in the control group (P = 0.02). Sudden cardiac death was numerically lower in the ICD group (3.1% vs. 5.9%; P = 0.521).